Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quality-Of-Life Data Favor Stenting Over Drugs In Short-Term

This article was originally published in The Pink Sheet Daily

Executive Summary

The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.

You may also be interested in...



Study Shows No Death, MI Advantages For Stenting Over Medical Therapy

Results form the 2,287-patient COURAGE trial presented the American College of Cardiology meeting should give physicians more to think about before moving forward with percutaneous coronary intervention in stable heart disease patients, researchers say.

Feds Try To Pave Path For Frustrated Pediatric Device Innovators

NIH and government agencies plan to submit plans to Congress next month describing ways to encourage the development of medical devices for children.

Legal Issues Abound For Device Marketers In The Blogosphere

Do not be cavalier about this venue, drug/device lawyer warns.

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel